We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Patients With Renal Impairment Undergoing CT

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00292487
First Posted: February 16, 2006
Last Update Posted: February 8, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Bracco Diagnostics, Inc
February 14, 2006
February 16, 2006
February 8, 2012
November 2004
February 2006   (Final data collection date for primary outcome measure)
Increase in SCr at 48-72 hours post dose
Same as current
Complete list of historical versions of study NCT00292487 on ClinicalTrials.gov Archive Site
  • Compare incidence of delayed hypersensitivity type reactions
  • Compare changes in heart rate
  • Compare efficacy of key vessels
Same as current
Not Provided
Not Provided
 
Patients With Renal Impairment Undergoing CT
Isovue and Visipaque in Renally Impaired Patients Undergoing CT
The purpose of the study is to compare the incidence of contrast induced nephrotoxicity following the administration of Isovue or Visipaque in patients with mild to moderate renal impairment who undergo a clinically indicated IV contrast-enhanced (multidetector computed tomography) MDCT of the liver or MDCT angiography of the lower extremities. Serum Creatinine (SCr) will be measured before and up to 48-72 hours post dose.
Not Provided
Interventional
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Diagnostic
Contrast Induced Nephropathy
Drug: Iopamidol 370 mgI/mL
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
150
February 2006
February 2006   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • referred for MDCT of liver or peripheral CTA
  • stable baseline SCr of 1.5 - 2.5 mg/dL and/or calculated CrCl of 10-60 mL/min

Exclusion Criteria:

  • unstable renal function
  • required prophylactic drugs to receive contrast (other than hydration)
  • uncontrolled diabetes
  • currently on dialysis
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00292487
IOP107
Not Provided
Not Provided
Not Provided
Not Provided
Bracco Diagnostics, Inc
Not Provided
Study Director: Marie Morris Bracco Diagnostics, Inc
Bracco Diagnostics, Inc
August 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP